Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)¹
07 févr. 2019 07h00 HE
|
Advanced Accelerator Applications
First ever approved Peptide Receptor Radionuclide Therapy in CanadaNeuroendocrine tumors are rare malignancies that affect approximately 12,000-15,000 Canadians2 SAINT-GENIS-POUILLY, France, Feb. ...
Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications
03 déc. 2018 03h00 HE
|
Advanced Accelerator Applications
Novel small molecule FF-10158 targets integrin alphavbeta3 (avβ3) and alphavbeta5 (avβ5) receptors Expands theragnostic pipeline Potential broad application in the detection and treatment of highly...
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
12 févr. 2018 07h00 HE
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a Novartis company and leader in nuclear medicine...
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer
01 févr. 2018 16h05 HE
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), a Novartis company and a leader in nuclear medicine...
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
26 janv. 2018 12h00 HE
|
Advanced Accelerator Applications
First-in-class Therapy Demonstrated 79% Improvement in Progression Free Survival in NETTER-1 Phase 3 Study in Midgut NET Patients LUTATHERA® marks first FDA Approval for a Peptide Receptor...
Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer
22 janv. 2018 08h00 HE
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), a leader in nuclear medicine theragnostics, today...
Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer
07 déc. 2017 07h00 HE
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced...
Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis
05 déc. 2017 16h00 HE
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced...
Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017
17 nov. 2017 07h39 HE
|
Advanced Accelerator Applications
$3.9 Billion All Cash Proposed Tender Offer by Novartis European Approval of Lutetium Lu 177 Dotatate* (Lutathera®) for GEP-NETs Recent Highlights: Sales for the third quarter of 2017 increased 39%...
Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis
30 oct. 2017 02h00 HE
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced...